echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Brain: The commonly used diabetes drug Essena peptide may be expected to help prevent or treat Parkinson's disease

    Brain: The commonly used diabetes drug Essena peptide may be expected to help prevent or treat Parkinson's disease

    • Last Update: 2020-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    3, 2020 // -- In a recent study published in the international journal Brain, scientists from University College London and others found that drugs to treat type 2 diabetes may reduce the risk of Parkinson's disease in patients. In the paper, researchers tested a drug called exenatide, which could be used as a potential treatment for Parkinson's disease in upcoming clinical trials, and the results support the redirection of diabetes drugs to treat Parkinson's disease. In the
    study, researchers analyzed the medical records of 100,288 people with type 2 diabetes from the Health Improvement Network database, and said people with type 2 diabetes were often at increased risk of Parkinson's disease compared to those who did not have type 2 diabetes, but the common therapeutic drugs: GLP-1 agonists and DPP4 inhibitors, did not appear to reverse the increased risk of Parkinson's disease.
    Photo Source: Wikipedia researchers found that patients who ate both GLP-1 agonists (e.g., DPP4 inhibitors) and two types of diabetes drugs may seem less likely to be diagnosed with Parkinson's disease in the next few years (with an average follow-up time of 3.3 years), while patients who take GLP-1 agonists are 60 percent less likely to develop Parkinson's disease.
    The study further confirms the results of the treatment of Patients with Parkinson's disease in Phase 3 clinical trials, and researchers will then recruit 200 patients with Parkinson's disease in the UK to conduct further trials, after previous studies suggested that Parkinson's patients who were injected with Essenalutide once a week may perform better in exercise testing than those who injected placebos.
    study reinforces the link between type 2 diabetes and Parkinson's disease, although researchers now know that most people with diabetes do not develop Parkinson's disease, said Foltynie, a researcher at the University of California, California.
    The researchers also added evidence that the drug Essena peptide may help prevent or treat Parkinson's disease by affecting the course of the patient's disease rather than simply alleviating the patient's symptoms, which, of course, may require more clinical trials by later scientists.
    finally, clinicians may need to consider other risk factors for Parkinson's disease when giving drugs to people with type 2 diabetes, but more research is needed later to confirm its clinical application value, the researchers said.
    () Original source: Ruth Brauer, Li Wei, Tiantian Ma, et al. Diabetes and risk of Parkinson's disease: a cohort study of patients with diabetes, Brain (2020). DOI: 10.1093/brain/awaa262
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.